An observational study in Cervical Artery Dissection and Pregnancy Complications, sponsored by University Hospital, Basel, Switzerland. Recruiting at 12 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.
Sponsored by University Hospital, Basel, Switzerland · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Pregnancy Complications with a site in United States — 39 open to participants now, 47 under way, 1 of them phase 3. Pregnancy Complications · United States.
Among the 127 studies in Pregnancy Complications with a site in United States, this one is the 17th largest by planned enrollment of the 61 observational ones that give a count, is one of 10 that started in 2023, is one of 61 observational ones, reaches primary completion later than 1 of the 46 other live ones, and was the 93rd registered.
411 studies on the registry are indexed under Pregnancy Complications; 111 are open to participants now.
Browse Pregnancy Complications studies →39 of the 127 studies in Pregnancy Complications with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 0 days–9 mo
University of Florida · Sites in United States
Ages 15–49 · Women only
Medicines360 · Sites in United States
Ages 18–99 · Women only · Healthy volunteers
Kenneth Moise MD · Sites in United States
Ages 18–45 · Women only
Michigan State University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Pregnancy Complications studies recruiting now, 43 (48%) set no upper age limit and 44 (49%) stop at 75 or younger; 22 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 8 · Phase 4 6
First in 1995; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 400 across 198 observational studies indexed under Pregnancy Complications.
Median enrollment 96 across the 66 interventional studies, 477 across the 61 observational. Of the 69 that completed or were terminated, 19 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 127 have an industry lead sponsor. The 10 most frequent:
University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.
University Hospital, Basel, Switzerland has 2 studies filed under Pregnancy Complications — fewer than ten, so there is no comparison to draw.
20 of the studies in Pregnancy Complications with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT04544462Genomic Prediction Inc.ANXA5 M2 Haplotyping in IVF Patients and Embryos | 2026-11 |
| NCT06529042Mount Sinai Hospital, CanadaSCRIPT: Sickle Cell Risk in Pregnancy Tool | 2026-12 |
| NCT06026969Children's National Research InstitutePregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure | 2026-12 |
| NCT06790043Albany Medical CollegeImpact of Patient Selected Visual Art in the Hospital Room During Antepartum Admission on Hospital Satisfaction Scores and Patient Experience | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 127 studies in Pregnancy Complications with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary objective: To determine whether pregnancy increases the risk of recurrent CeAD and delayed stroke in women with prior CeAD based on long-term data.
Methods: Multicentric, observational case-control study based on pooled individual patient data from several stroke centers.
Primary endpoint: Primary composite outcome measure includes the following outcomes: (i) occurrence of recurrent CeAD, (ii) occurrence of ischemic or hemorrhagic stroke, (iii) death.
Background: Cervical artery dissection (CeAD) is a leading cause of stroke in women of childbearing age. Among the population with an initial CeAD, about 9% show a recurrence event (a range from 0 to 25% has been reported). Recurrence of CeAD can occur for several years after the initial event. CeAD has been shown to occur in association with pregnancy, and the postpartum period, yet it remains unclear whether pregnancy increases the risk of recurrence or delayed stroke. Previous studies on this subject are either based on small sample sizes or lack long-term data.
Objective: The investigators want to determine whether pregnancy increases the risk of recurrent CeAD and delayed stroke in women with prior CeAD based on long-term data.
Furthermore, it will be investigated whether the mode of delivery affects recurrence and if dissections occurred during a particular phase of a woman's reproductive process. The investigators will also investigate if women actively decided against another pregnancy due to the initial CeAD.
Methods: This study will be a multicenter, exploratory case-control study using pooled individual patient data from several stroke centers. The data will be obtained through review of medical records and patient interviews. The study will include all women with any prior CeAD who have had long-term follow-up (at least 6 months, with no upper limit), including information about pregnancy and recurrence of CeAD.
Primary endpoint is a composite outcome measure which consists of (i) occurrence of recurrent CeAD, (ii) occurrence of ischemic or hemorrhagic stroke, (iii) death. Secondary endpoints are the individual components of the primary endpoint and functional outcome assessed by the modified Ranking scale.
Statistical analysis will be used to determine the odds of the primary and secondary endpoints in women who had subsequent pregnancies compared to those who did not.
Female patients aged ≥18 years with prior CeAD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women who became pregnant at least once after first index CeAD
Women who did not became pregnant after first index CeAD
Number of participants with composite outcome measure - recurrent CeAD, ischemic stroke, hemorrhagic stroke and/or death
The composite outcome measure includes the following outcome measures during the follow-up: (i) occurence of recurrent cervical artery dissection (CeAD), (ii) occurrence of any ischemic stroke, (iii) occurrence of any hemorrhagic stroke, (iv) death.
Time frame: From date of first CeAD until date of latest follow-up assessed up to 35 years
Number of participants with recurrent cervical artery dissection
assessed by medical history or clinical suspicion with confirmation by cerebrovascular imaging (MRI, MRI angiography, CT, CT angiography, digital subtraction angiography and/or ultrasound)
Time frame: From date of first CeAD until date of latest follow-up assessed up to 35 years
Number of participants with new ischemic stroke
assessed by medical history or clinical suspicion with confirmation by cerebrovascular imaging (MRI and/or CT)
Time frame: From date of first CeAD until date of latest follow-up assessed up to 35 years
Number of participants with new hemorrhagic stroke
Intracerebral hemorrhage or subarachnoid hemorrhage assessed by medical history or clinical suspicion with confirmation by cerebrovascular imaging (MRI and/or CT)
Time frame: From date of first CeAD until date of latest follow-up assessed up to 35 years
Number of participants with death
Time frame: From date of first CeAD until date of latest follow-up assessed up to 35 years
Functional outcome as assessed by modified Rankin Scale (mRS)
The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. 1. - No significant disability. Able to carry out all usual activities, despite some symptoms. 2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. - Moderate disability. Requires some help, but able to walk unassisted. 4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. - Dead.
Time frame: At date of latest, individual follow-up assessed up to 35 years after first CeAD
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2023 to primary completion in Dec 2024, 23 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland →